

Supplementary Table 1. Patient characteristics

Patients		CDEI before	CDEI after	SES-CD before	SES-CD after	Gender	Montreal classification*			weeks between biopsies	Age at inclusion (years)	anti-TNF **
							A1/A2/A3	L1/L2/L3/L4	B1/B2/B3/+p			
Responders	1	37	0			F	2	3	1	8	23	IFX
	2	38.5	10			M	1	3	3	8	39	ADA
	3			18	11	M	2	3	2	183	25	ADA
	4			3	1	F	2	3	2	17	20	ADA
	5			22	9	F	2	3	2p	129	56	ADA
	6			4	0	F	2	3	2	66	35	ADA
	7			27	0	F	2	3	1	13	40	ADA
Non-responders	8	5.2	6.4			F	2	1	1	8	31	ADA
	9	19	19.8			F	2	3	2	8	23	IFX
	10	4	8			M	2	3	2	8	61	ADA
	11	3.2	6.76			M	2	1	2	8	20	ADA
	12			3	3	M	2	3+4	3p	29	39	ADA
	13			5	4	M	2	3	3	20	48	ADA
	14			15	15	F	2	3	3p	54	51	ADA

CDEI= Crohn's Disease Endoscopic Index for severity, SES-CD= Simple Endoscopic Severity Crohn's Disease.\* Montreal classification: Age at diagnosis: A1: <17 years, A2: 17–40 years, A3: >40 years; Maximal location of disease: L1: ileal, L2: colonic, L3: ileocolonic, L4: upper disease; Maximal disease behaviour: B1: non-stricturing, non-penetrating, B2: stricturing, B3: penetrating, p: perianal disease. \*\* IFX: Infliximab, ADA: Adalimumab